Literature DB >> 19755599

Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls.

Pamela T Johnson1, Karen M Horton, Elliot K Fishman.   

Abstract

The adrenal gland is involved by a range of neoplasms, including primary and metastatic malignant tumors; however, the most common tumor detected is the incidental benign adenoma. Although computed tomographic (CT) findings will not always yield a definitive diagnosis, attention to these findings provides a road map to guide image interpretation. Adenomas typically demonstrate rapid washout, which is defined as an absolute percentage washout (APW) of more than 60% and a relative percentage washout (RPW) of more than 40% on delayed images. Adrenocortical carcinoma typically has an RPW of less than 40%; however, large size and heterogeneity are more reliable indicators of the diagnosis than are washout values. Washout characteristics of pheochromocytoma are variable; in conjunction with high levels of dynamic enhancement, pheochromocytomas may mimic adenoma (ie, APW > 60%, RPW > 40%). Myelolipomas appear as well-defined masses with variable quantities of fat and soft tissue. After contrast material administration, metastases usually demonstrate slower washout on delayed images (APW < 60%, RPW < 40%) than do adenomas, although hypervascular metastases may enhance similarly to pheochromocytoma. Finally, a number of nonadrenal pathologic conditions have been reported to mimic adrenal masses at CT. (c) RSNA, 2009.

Entities:  

Mesh:

Year:  2009        PMID: 19755599     DOI: 10.1148/rg.295095027

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  37 in total

Review 1.  CT and MRI of adrenal gland pathologies.

Authors:  Fuqin Wang; Junwei Liu; Ruoxi Zhang; Yonghua Bai; Cailin Li; Bangguo Li; Heng Liu; Tijiang Zhang
Journal:  Quant Imaging Med Surg       Date:  2018-09

Review 2.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

Review 3.  The indeterminate adrenal mass.

Authors:  Barney Harrison
Journal:  Langenbecks Arch Surg       Date:  2011-09-23       Impact factor: 3.445

Review 4.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 5.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

6.  Collision and composition tumors: rare conditions to remember in differential diagnosis of adrenal glands lesions.

Authors:  Giuseppe Cicero; Alfredo Blandino; Stefano Pergolizzi; Giorgio Ascenti; Silvio Mazziotti
Journal:  Quant Imaging Med Surg       Date:  2019-11

Review 7.  Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.

Authors:  Asha Kandathil; Ka Kit Wong; Daniel J Wale; Maria Chiara Zatelli; Anna Margherita Maffione; Milton D Gross; Domenico Rubello
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

Review 8.  Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses.

Authors:  Jung Jae Park; Byung Kwan Park; Chan Kyo Kim
Journal:  Br J Radiol       Date:  2016-03-02       Impact factor: 3.039

9.  Distinguishing pheochromocytoma from adrenal adenoma by using modified computed tomography criteria.

Authors:  Sohi Kang; Young Lyun Oh; Sung Yoon Park
Journal:  Abdom Radiol (NY)       Date:  2020-09-20

10.  Computed tomography of adrenocortical carcinoma containing macroscopic fat.

Authors:  Nathan Egbert; Khaled M Elsayes; Shadi Azar; Elaine M Caoili
Journal:  Cancer Imaging       Date:  2010-11-09       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.